Vertex provided 2025 revenue guidance of $11.75 billion to $12 billion, reflecting 8% growth at the midpoint. Growth is expected from U.S. launches of ALYFTREK and JOURNAVX, along with the continued ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results , with sales up 15.7% year on year to $2.91 ...

Vertex sees 2025 revenue of $11.75 billion to $12.0 billion, the midpoint of which is above analysts' average expectation of ...

The fourth-quarter earnings season for the biotech sector is in full swing this week. A few bigwigs have already reported results. Among these, Bristol Myers reported better-than-expected ...

Four different Kentucky lobbyists made more than $1 million for their efforts to influence policy and government over the ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Keep your eye on the ball” is a motto for many athletes—and for astronomers trying to find Earth-threatening space rocks ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...